**MINUTES**

**CPIC CONFERENCE CALL**

DATE: February 5, 2014

PRESENT: Andrea Gaedigk, Cindy Prows, Dan Hertz, Dan Roden, Daniel Muller, David Bright, Deanna Kroetz, Ellie McDonagh, Gillian Bell, James Hoffman, Jasmine Talameh, Jason Mayes, Julia Barbarino, Tom Callaghan, Katrin Sangkuhl, Kevin Hicks, Kelly Caudle, Kristen Weitzel, Li Gong, Lynn Dressler, Matthias Schwab, Mia Wadelius, Michelle Whirl-Carrillo, Nita Limdi, Philip Empey, Ravie Kem, Robert Freimuth, Sam Johnson, Sander Vinks, Simona Volpi, Steve Leeder, Stuart Scott, Sunday Obri, Teri Klein, Todd Skaar, Trish Brown, Vojtech Huser

| TOPIC | DISCUSSION/ACTION | FOLLOW-UP |
| --- | --- | --- |
| Update on CPIC guidelines in progress | - *CFTR*/ivacaftor: In revision with CPT  -*G6PD/*rasburicase guideline: submitted  - *IL28B*/pegIntron: accepted; published on-line  *- CYP2C9*/ *HLA-B*/phenytoin: Writing underway.  -*CYP2D6*/SSRI: Authorship plan approved by CPIC Steering Committee; evidence review underway  -*CYP3A5*/tacrolimus: Evidence review underway  Guideline Updates:  -Codeine guideline update: accepted  -*HLA-B*/abacavir: in revision  -*SLCO1B1*/simvastatin: Will be a major update (update to manuscript and supplement); underway | Kelly will follow-up on progress. |
| CPIC Process paper published | The CPIC guideline development process paper is now published in a special issue of *Current Drug Metabolism* entitled “CLINICAL USE OF BIOMARKERS IN DRUG METABOLISM AND ADVERSE DRUG REACTIONS” (<http://www.ncbi.nlm.nih.gov/pubmed/24479687>). The purpose of this paper was to describe the development process of the CPIC guidelines and to compare our process to the Institute of Medicine’s (IOM) Standards for Developing Trustworthy Clinical Practice Guidelines. | Paper will be posted on PharmGKB and available free access through the publisher. |
| Warfarin guideline update | There have been several recently published studies on warfarin pharmacogenetics (PMID: 24251361, 24251363, 24251360). An additional study (GIFT) will be presented and published sometime in late 2014. Once the GIFT trial is published all of these studies will be incorporated into the next update of the CPIC guideline on warfarin (starting guideline update process in March 2014). PharmGKB has posted an announcement regarding these studies and the warfarin update on their website (http://www.pharmgkb.org/drug/PA451906). | Julie will follow-up on progress. Kelly will schedule conference call for guideline writing committee. |
| CPIC gene/drug pairs | A list of potential CPIC gene/drug pairs was presented. This list includes: 25 guidelines (includes 13 genes and 63 drugs), 10 evaluations (includes 7 genes and 36 drugs), and 52 PharmGKB annotations (includes 44 genes and 50 drugs). Initial prioritization was based on if the gene was already a topic of a CPIC guideline, strength of evidence to support actionable recommendation, and degree of testing. Prioritization of gene-drug pairs will change as new evidence is published. | PharmGKB/Kelly will continue to evaluate evidence and update list accordingly. Send any comments/additions to Kelly (Kelly.caudle@stjude.org). |
| Response to query on proposed LCD for 2C19, 2D6, 2C9, VKORC1 | CPIC leadership was contacted by GENETWORx and asked to comment on this proposed local coverage determination (LCD) (attached), which severely limits financial reimbursement for pharmacogenetic tests involving genes and/or drugs that are the subject of CPIC guidelines (2C19, 2D6, 2C9, VKORC1). CPIC sent the following response, “The CPIC Steering Committee has also discussed this document, which we have also shared with the senior authors of the relevant CPIC guidelines. As individual clinicians and pharmacogenetics experts, our authors are likely to disagree strongly with the recommendations of this document, and they are welcome to comment as individuals. However, we don’t think we can comment from CPIC officially—primarily because CPIC’s stance is that CPIC provides guidance on HOW to use genetic test results, not whether or how they should be ordered or how they might be reimbursed.” | CPIC members are welcome to send individual responses to this LCD. |
| CPIC informatics working group update | -We received positive comments from reviewers regarding informatics additions on the abacavir supplement. One reviewer asked for discussion regarding alert fatigue. Addressed comments and resubmitted manuscript.  -Progress being made on SLCO1B1/simvastatin guideline update and will include a much larger translation table (over 200 rows) than abacavir guideline. Working through details now. Will present on March CPIC conference call.  -Planning for supplement materials for additional guidelines | James, Michelle, and Bob will continue to update CPIC group on progress. |